🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — May 02, 2026

These five civilian federal contracts total $1,718,415,049 in obligations with 0/5 defense-related, spanning DOE nuclear materials, USDA IT software, HHS health R&D, GSA financial services, and DHS Coast Guard IT support. Dominant themes include strategic low-enriched uranium production via DOE's $900M award to ORANO FEDERAL SERVICES LLC and enterprise Salesforce support via USDA's $294.6M award to CARAHSOFT TECHNOLOGY CORP, signaling civilian agency commitments to critical infrastructure and IT modernization. Highest-conviction signal is bullish for CARAHSOFT TECHNOLOGY CORP (strength 8/10) due to full obligation and outlays on its 5-year USDA contract. ORANO FEDERAL SERVICES LLC's $900M DOE award offers the largest materiality (9/10) for long-term nuclear capacity. Key risk is high pricing risk on firm fixed price structures across ORANO, CARAHSOFT, GLOBAL HEALTH INVESTMENT CORPORATION, and BANK OF NEW YORK MELLON contracts, with watch on initial outlays for ORANO post-May 1, 2026.

5 total filings
· daily

Biotech Small-Cap Approvals — May 01, 2026

The period captured 1 FDA approval in the biotech small-cap stream: 0 NMEs, 0 biosimilars (classified as 1 other/fallback), 0 label expansions. Micro Labs' ticagrelor approval (2026-04-27) delivers a single neutral signal (strength 5/10, materiality 5/10), representing fallback biosimilar entry with all commercial metrics NOT_DISCLOSED, including peak sales, exclusivity, pricing power, and market position. No dominant therapeutic area theme emerges from this lone approval. Highest-conviction signal is ticagrelor by Micro Labs, implying modest, neutral commercial access for the entrant alongside potential erosion risk for the originator. Key risk/watch item: lack of disclosed commercial data obscures launch potential and competitive dynamics for Micro Labs and ticagrelor originator.

1 total filings
· daily

Big Pharma Approvals — May 01, 2026

FDA approvals from May 01, 2026 to May 01, 2026 in the Big Pharma stream totaled 1: 0 NME(s), 0 Biosimilar(s), 0 Label Expansion(s), 1 Other. AstraZeneca AB's BUDESONIDE (BREZTRI AEROSPHERE) label expansion approval delivers the period's highest-conviction bullish signal (strength 5/10, materiality 5/10), potentially strengthening its market position in an undisclosed therapeutic area despite all commercial metrics (peak sales, exclusivity, pricing) remaining NOT_DISCLOSED. No dominant therapeutic area theme is evident from this solitary approval. Balanced upside exists via expanded labeling, but risks include lack of disclosed near-term catalysts (N/A) and opaque market positioning. Key risk/watch item: monitor post-approval uptake and any emerging competitive dynamics for BREZTRI AEROSPHERE.

1 total filings
· daily

Orphan Drug Approvals — May 01, 2026

In the May 01, 2026 period, the FDA approved 1 orphan drug (0 NME, 0 biosimilar, 0 label expansion, 1 other), marking a bullish signal in the orphan space. Daiichi Sankyo's FAM-TRASTUZUMAB DERUXTECAN-NXKI (ENHERTU) label expansion represents the highest-conviction event, signaling potential upside in orphan indications with a strength of 5/10 and materiality of 5/10. No dominant therapeutic area theme emerges from this single approval. Key commercial details including peak sales, exclusivity, pricing power, and market position remain NOT_DISCLOSED, tempering near-term visibility. Investors should watch for post-approval uptake and any confirmatory data requirements inherent in orphan expansions.

1 total filings
· daily

New Drug Approvals (Original) — May 01, 2026

FDA approvals from May 01, 2026 to May 01, 2026 totaled 1, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other. Micro Labs secured FDA approval for TICAGRELOR, a fallback approval categorized as neutral (strength 5/10, materiality 5/10) with no disclosed peak sales, exclusivity, pricing, or market position data. No dominant therapeutic area theme emerged from this single approval. The highest-conviction signal is Micro Labs' TICAGRELOR approval, offering neutral commercial implications as a market entrant with limited near-term catalysts. Key risk/watch item: competitive pressure on AstraZeneca's originator TICAGRELOR (Brilinta) from this new entrant, potentially leading to revenue erosion.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — May 01, 2026

A single $400,000,000 firm fixed price delivery order awarded by the U.S. Coast Guard (DHS) to The Whiting-Turner Contracting Company drives the entire period's aggregate, representing 100% civilian infrastructure spending with zero defense-related contracts. The award funds accelerated design-build construction of barracks, multi-use training facility, galley, and firehouse at USCG TRACEN Cape May, NJ, under full and open competition, signaling bullish future revenue potential (~$100M annually over ~4 years to 2030-05-06). Highest-conviction signal is bullish for Whiting-Turner due to the significant obligation and non-small business win in commercial/institutional building construction (NAICS 236220). Key risk is high contract pricing risk on the firm fixed price structure with $0 outlayed to date, vulnerable to execution delays. Investors should monitor outlay progress and performance milestones amid neutral sector trends in Coast Guard miscellaneous buildings (PSC Y1JZ).

1 total filings
· daily

DHS Homeland Security Contracts — May 01, 2026

DHS Homeland Security contracts totaling $494,743,378 over the period highlight civilian infrastructure and disaster recovery spending, with 0/2 defense-related awards focused on U.S. Coast Guard and FEMA priorities. The highest-materiality signal is Whiting-Turner Contracting Company's $400,000,000 firm fixed-price delivery order for Coast Guard facility construction at Cape May, NJ, representing ~81% of aggregate value and a ~$100M annual revenue estimate over four years. Jacobs Engineering Group Inc. (via CH2M HILL - CDM PA-TAC RECOVERY SERVICES) adds $94,743,378 in confirmed FEMA disaster recovery consulting revenue, with $88,083,223 already outlayed. Both full and open competition awards are bullish for sustained DHS civilian outlays. Key risk: zero outlays to date on the $400M Whiting-Turner contract signals execution dependency.

2 total filings
· daily

New Federal Contractors — May 01, 2026

These 5 new federal contracts total $940,833,149 in obligations, with 0/5 defense-related and all civilian awards split across DHS ($494.7M), HHS ($335.5M), and DOT ($110.6M). Dominant themes include DHS-led infrastructure construction and disaster recovery alongside HHS IT services continuity. Highest-conviction bullish signal is Whiting-Turner Contracting Company's $400M firm fixed-price Coast Guard barracks construction award, signaling multi-year revenue visibility through 2030. Balanced by neutral signals from long-running HHS IT contracts with low outlays ($0-$28M disbursed). Key risk is high pricing risk on firm fixed-price structures and stalled outlays; watch outlay progress across all contracts, especially Whiting-Turner's $0 initial disbursement.

5 total filings
· daily

Significant Contract Modifications ($10M+) — May 01, 2026

These six significant contract modifications total $941,279,215 in obligations, entirely civilian with zero defense-related awards, highlighting sustained non-DOD federal spending in construction, IT services, and modernization. Dominant themes include DHS investments ($494.7M across Coast Guard barracks construction and FEMA disaster recovery) and HHS IT/data services ($335.5M). Highest-conviction bullish signal is Whiting-Turner Contracting Company's $400M firm fixed price delivery order for USCG TRACEN Cape May facilities, signaling multi-year revenue through 2030. Key risk is high pricing risk on firm fixed price structures across multiple awards, compounded by $0 outlays on three contracts (Whiting-Turner, Lockheed Martin Services, Lockheed Martin Corp). Watch outlay progress and performance extensions, especially for dated contracts like Lockheed Martin Services (current end 2017-09-30).

6 total filings
· daily

Contract Deobligations Alert — May 01, 2026

This Contract Deobligations Alert covers six civilian agency contracts totaling $941,279,215 in obligations, with 0/6 defense-related, highlighting infrastructure, IT services, and modernization themes across DHS (Coast Guard/FEMA), HHS, DOT (FAA), and Commerce (NOAA). Dominant agencies are DHS ($494.7M or 53%) and HHS ($335.5M or 36%), with bullish signals on Whiting-Turner Contracting Company's $400M Coast Guard construction (highest materiality at 8/10) and Frequentis USA's $110.6M FAA VCS modernization providing the strongest revenue visibility. CH2M HILL (Jacobs) $94.7M FEMA disaster recovery shows 93% outlay progress ($88.1M disbursed), confirming near-term cash flow. Key risk is execution uncertainty from $0 outlays on three major contracts (Whiting-Turner $400M, Lockheed Martin Services $225M, Lockheed Martin $446k), signaling potential deobligation or delays in firm fixed-price structures.

6 total filings
· daily

Contract Option Exercises — May 01, 2026

These 6 contract option exercises total $941,279,215 in obligations, entirely civilian (0/6 defense-related) with an average signal strength of 4.8/10, spanning DHS, HHS, DOT, and DOC agencies. Dominant themes include DHS infrastructure construction via Whiting-Turner Contracting Company's $400M Coast Guard barracks project and FEMA disaster recovery via Jacobs Engineering's $94.7M Hermit's Peak fire claims support, alongside FAA modernization by Frequentis USA ($110.6M). Highest-conviction bullish signal is Whiting-Turner's $400M firm-fixed price award under full competition, signaling ~$100M annual revenue over 4 years despite $0 outlays to date. Key risk is high pricing risk on firm-fixed contracts and $0 outlays across multiple awards (Whiting-Turner, Lockheed Martin Services $225M HHS, Lockheed Martin $446K NOAA), warranting outlay monitoring amid CR uncertainty.

6 total filings
· daily

Federal Professional Services Contracts — May 01, 2026

Jacobs Engineering Group Inc., through its CH2M HILL - CDM PA-TAC RECOVERY SERVICES subsidiary, captured a $94,743,378 DHS/FEMA delivery order for Hermit Peak Calf Canyon Fire disaster recovery consulting, representing 100% civilian exposure with zero defense contracts in this period. The Time and Materials award under full and open competition confirms $88,083,223 in outlays (93% of total), yielding ~$37-38M gross annual revenue and ~$12M net after $64,826,881 in subawards. Highest-conviction bullish signal stems from substantial revenue recognition in sustained FEMA emergency response spending (NAICS 541611, PSC R429). Key watch item: remaining ~$6.6M outlays and contract performance end date of 2025-08-15, with medium pricing risk and high subaward reliance potentially pressuring prime margins.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — May 01, 2026

Two neutral-rated federal IT & cybersecurity contracts totaling $335,513,583 in obligations were analyzed, with 0/2 defense-related (100% civilian HHS exposure). The dominant agency theme is Department of Health and Human Services (HHS), focusing on long-term IT facilities management (Lockheed Martin Services, LLC $225M) and computing infrastructure/data processing (Companion Data Services LLC $110M). Highest-conviction signal is neutral steady spend in civilian IT, diversifying Lockheed Martin Corp from defense reliance. Key risk is execution uncertainty from $0 outlayed on Lockheed's contract (despite $225M obligation) and only 26% ($28M) outlayed on Companion's $110M obligation. Investors in Lockheed Martin Corp (LMT) should watch for outlay acceleration and option exercises amid average signal strength of 4.0/10.

2 total filings
· daily

All HHS Contracts — May 01, 2026

HHS awarded two civilian IT contracts totaling $335,513,583 in obligations during the May 2026 period, with 0% defense-related exposure across both awards to Lockheed Martin Services, LLC ($225M) and Companion Data Services LLC ($110M). The dominant theme is long-term HHS IT facilities management and data processing services via firm fixed price delivery orders, both under full and open competition with neutral investment signals (avg 4/10 strength). Highest-conviction signal is neutral diversification for Lockheed Martin Corp into civilian HHS work, offset by execution uncertainties. Key risk is minimal outlays—$0 for Lockheed and only 26% ($28M) for Companion—amid past or nearing end dates, signaling potential non-performance or delays.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — May 01, 2026

Four civilian mega contracts totaling $846,089,770 (0/4 defense-related) highlight steady but uneven spending across DHS Coast Guard construction, DOT FAA telecom modernization, and HHS IT services, with no dominant agency theme beyond HHS's two awards ($335M combined). Highest-conviction bullish signal is Whiting-Turner Contracting Company's $400M firm fixed-price barracks construction award from USCG, signaling ~$100M annual revenue potential over 4 years despite $0 outlays to date. Frequentis USA's $110M FAA VCS modernization adds positive tech upgrade momentum with $25M already outlayed. Key risk is high pricing risk and $0 outlays on the two largest contracts (Whiting-Turner $400M and Lockheed Martin $225M), warranting close monitoring of fund releases amid firm fixed-price structures.

4 total filings
· daily

High-Value Federal Grants ($5M+) — May 01, 2026

These five high-value civilian federal contracts total $940,833,149 in obligations with 0/5 defense-related, highlighting sustained non-DOD spending led by DHS (Coast Guard/FEMA) and HHS agencies in construction, IT services, and disaster recovery. Dominant themes include DHS infrastructure builds and emergency response alongside HHS/CMS IT support, with the highest-conviction bullish signal being Whiting-Turner Contracting Company's $400M Coast Guard barracks construction award under full competition. Frequentis USA's $110M FAA VCS modernization and Jacobs Engineering's (via CH2M HILL) $94M FEMA fire claims support add revenue visibility through 2027. Key risk is zero outlays on the two largest contracts (Whiting-Turner $400M and Lockheed Martin $225M), signaling execution uncertainty despite firm fixed-price structures.

5 total filings
· daily

General Federal Contracts — May 01, 2026

These five civilian contracts total $940,833,149 in obligations, with 0 defense-related awards, highlighting sustained federal civilian spending in construction, IT services, and disaster recovery. Dominant themes include DHS infrastructure projects (Whiting-Turner $400M Coast Guard construction and Jacobs $95M FEMA consulting) and HHS IT sustainment (Lockheed Martin $225M and Companion Data $110M). The highest-conviction bullish signal is Whiting-Turner's $400M firm fixed-price delivery order for Coast Guard facilities at Cape May, NJ, signaling multi-year revenue visibility through 2030. Key risk is zero outlays to date on the two largest contracts (Whiting-Turner $400M and Lockheed Martin $225M), flagging execution uncertainty amid high pricing risks.

5 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 01, 2026

Across 31 filings from the USA S&P 500 Technology stream (broadly including adjacent sectors like telecom and software), Q1 2026 results show mixed performance with 12/17 quarterly reporters posting YoY revenue growth averaging +11% (led by Apple +16.5%, Cadence +19%, Iradimed +12.6-13%), but profitability pressures evident in 8/17 cases with net losses widening or income declining (e.g., Shentel net loss $15.8M vs $9.1M, Smurfit operating profit -54%). Acquisitions drove asset growth and cash burn in Cadence (-53% cash QoQ), Verizon (-56% cash QoQ), and Atmus (debt +$455M), while capital returns remained robust via buybacks (Apple $36B 6-mo, Verizon $2.5B Q1, Cadence $200M Q1) and dividends (Iradimed $0.20/sh, Atmus $0.055/sh). Forward guidance was largely reaffirmed (Shentel rev $370-377M, Iradimed FY $91-96M, Atmus sales $1.945-2.015B), but risks from restatements (Ducommun overstating NI $9.8M FY24) and workforce cuts (Shentel 10%) signal caution. Sentiment is mixed/neutral overall (20/31 mixed/neutral), with tech outliers like Apple and Cadence showing strength amid sector capex intensity. Portfolio-level trends point to revenue resilience but margin compression in 6/10 key filers (-150bps avg where reported) and ongoing M&A for growth.

17 high priority 14 medium 31 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 01, 2026

Across 30 filings from NASDAQ-100 related entities, Q1 2026 results reveal resilient revenue growth averaging 8.2% YoY (Apple +16.5%, Atmus +14.7%, Iradimed +12.6-13%, Verizon +2.9%, Shenandoah +4.8%), but profitability mixed with compressions in 6/12 reporters (Smurfit operating profit -54.2%, Shenandoah net loss widened to $15.8M from $9.1M, TXNM earnings -58.1%). Capital allocation remains shareholder-friendly with $36B Apple buybacks, $2.5B Verizon repurchases, steady dividends (Kennametal $0.20, Iradimed $0.20, Atmus $0.055), and gains from divestitures (First Community $10M pre-tax). M&A activity accelerates (Verizon $9.48B acquisitions boosting goodwill +34%, Atmus Koch Filter adding $456M net assets, TXNM Blackstone deal pending H2 2026 at $61.25/share). Risks emerge from accounting errors (Ducommun restatements overstating net income $9.8M FY2024), workforce cuts (Shenandoah 10% RIF saving $12.3M annually from 2027), and low AGM participation (Aditxt 34.17%). Forward guidance stable (Iradimed FY2026 rev $91-96M, Atmus $1.945-2.015B, Shenandoah $370-377M), signaling sector resilience amid macro pressures. Portfolio-level trend: Industrials/tech outperform telecom/energy on growth, with buybacks signaling management conviction.

13 high priority 17 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 01, 2026

The 50 filings from S&P 500 Financials and adjacent sectors reveal mixed Q1 2026 results, with average revenue growth of +11% YoY across 25 reporting companies (e.g., Ares +strong fundraising, BNY Mellon +13%), but frequent margin compression (-100 bps avg in 8/15 industrials/financial services) and negative cash flows in 12 firms (e.g., Cinemark $(20.4)M op CF, Ryan Specialty $(167)M). Asset managers excelled with AUM/AUC/A growth averaging 15% YoY (Ares +18%, BNY +12% AUC/A, TPG $306B), driving fee income surges (+25% Ares), while banks/insurers showed resilient capital returns via dividends/buybacks totaling >$1B (News Corp $1B program, Verizon $2.5B repurchases). M&A activity heated up with 6 deals (UWM revised Two Harbors offer at $12 cash/2.33x, Esperion 58% premium acquisition, Stock Yards Field & Main), signaling consolidation. Capital allocation favors shareholders (18 firms: div hikes Piper +14%, buybacks Ryan $40M), but debt rises (Shenandoah +10%, Dream Finders +17% QoQ) and outflows (Virtus $(8.4)B) flag caution. Guidance mixed: 7 raises (Newell flat to +2%, Piper low-double digits), 3 cuts (Fulgent Non-GAAP loss to $(1.59)). Portfolio implication: Overweight asset managers/financial services on AUM tailwinds, underweight cyclicals amid cash burn; monitor Q2 catalysts like div record dates in June.

15 high priority 35 medium 50 total filings